Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data

Published:2024-06-11 Issue: Volume: Page:1-9
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Abé Christoph¹²^ORCID,Keto Jaana³^ORCID,Lilja Mathias¹^ORCID,Konradsen Mie⁴^ORCID,Mesterton Johan¹⁵^ORCID,Höglund Martin⁶,Lazarevic Vladimir⁷^ORCID,Lehmann Sören⁶⁸⁹,Juliusson Gunnar⁷^ORCID

Affiliation:

1. Quantify Research, Stockholm, Sweden

2. Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

3. Jazz Pharmaceuticals, Copenhagen, Denmark

4. Quantify Research, Copenhagen, Denmark

5. Medical Management Centre, Karolinska Institutet, Stockholm, Sweden

6. Department of Medical Sciences, Uppsala University, Uppsala, Sweden

7. Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, Lund, Sweden

8. Department of Medicine, Karolinska Institute, Solna, Sweden

9. Department of Hematology, Academic Hospital, Uppsala, Sweden

Funder

Jazz Pharmaceuticals Nordics ApS

Cancerfonden

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2363430

Reference31 articles.

1. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

2. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period

3. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

4. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

5. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3